Summer Y.Y. Ha

The University of Texas Health Science Center at Houston — United States

Medicine · Health Sciences

9h-index654citations31works27.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(23), Monoclonal and Polyclonal Antibodies Research(14), Radiopharmaceutical Chemistry and Applications(13), Nanoplatforms for cancer theranostics(6), Photodynamic Therapy Research Studies(6)

Publications31 total

177Lu-labeled antibody-drug conjugate: a dual mechanistic treatment modality in solid tumors with heterogeneous antigen expression

Nuclear Medicine and Biology·2025Open Access

Data from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S1 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S8 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Table S1 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S9 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Table S2 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S7 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S5 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S10 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S4 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S3 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S2 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

Supplementary Figure S6 from 177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

2025Open Access

177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors

6 cited

Molecular Cancer Therapeutics·2025· 6 cited

Exploring the next generation of antibody–drug conjugates

427 cited

Nature Reviews Clinical Oncology·2024· 427 citedOpen Access

Supplementary Data from An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody–Drug Conjugates

2023Open Access

Supplementary Data from An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody–Drug Conjugates

2023Open Access

Data from An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody–Drug Conjugates

2023Open Access

Data from An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody–Drug Conjugates

2023Open Access

page 1 of 2Next →

Frequent Co-authors

Kyoji Tsuchikama(24), Yasuaki Anami(24), Wei Xiong(23), Ningyan Zhang(23), Zhiqiang An(23), Chisato M. Yamazaki(21), Aiko Yamaguchi(18), Robert T. Ta(15), H. Charles Manning(14), Dennis K. P. Ng(7), Jangsoon Lee(6), Naoto T. Ueno(6), Candice M. Haase(5), Scott D. Olson(5), Clarence T. T. Wong(3), Yoshihiro Otani(2), Balveen Kaur(2), Wing‐Ping Fong(2), Roy C. H. Wong(2), Jacky C. H. Chu(2)